Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Fluidigm Expects 8 Percent Drop in Q1 Revenues, Withdraws 2020 Guidance

Fluidigm Expects 8 Percent Drop in Q1 Revenues, Withdraws 2020 Guidance

Apr 14, 2020
|
staff reporter

NEW YORK – Fluidigm said after the close of the market on Tuesday that it expects Q1 revenues of approximately $27.6 million.

Expected revenues would represent an 8 percent year-over-year decline from $30.1 million a year ago and fall short of analysts' average expectation of $29.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Test Evaluations

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

Justification for Stricter Standards Sought

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

Concerns Over Comment

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

PLOS Papers on Tremor Condition, Medical Plant Populations, Brewing Yeast Transcriptomics

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
01
Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

What's Popular?

In PCR

  1. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  2. FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

  3. Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

    Premium

  4. NIH Awardee MatMaCorp Developing SARS-CoV-2 Molecular Test for Rural Hospitals

    Premium

  5. BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.